Page last updated: 2024-12-07
4'-deoxydoxorubicinol
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
4'-deoxydoxorubicinol: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 128975 |
MeSH ID | M0134892 |
Synonyms (10)
Synonym |
---|
5,12-naphthacenedione, 10-((4-aminotetrahydro-6-methyl-2h-pyran-2-yl)oxy)-8-(1,2-dihydroxyethyl)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy- |
89780-72-3 |
7-(4-azanyl-6-methyl-oxan-2-yl)oxy-9-[1,2-bis(oxidanyl)ethyl]-4-methoxy-6,9,11-tris(oxidanyl)-8,10-dihydro-7h-tetracene-5,12-dione |
A845310 |
7-[(4-amino-6-methyl-2-oxanyl)oxy]-9-(1,2-dihydroxyethyl)-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione |
4-dol |
4'-deoxydoxorubicinol |
DTXSID001008968 |
10-[(4-amino-6-methyloxan-2-yl)oxy]-8-(1,2-dihydroxyethyl)-6,8,11-trihydroxy-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione |
epirubicin, ellence |
Research Excerpts
Pharmacokinetics
Excerpt | Reference | Relevance |
---|---|---|
"1 of paclitaxel suggests that the drugs might also interact at the pharmacodynamic level." | ( Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients. Baldini, E; Bocci, G; Conte, PF; Danesi, R; Del Tacca, M; Di Paolo, A; Fogli, S; Gennari, A; Innocenti, F; Salvadori, B, 2002) | 0.31 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (7)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 2 (28.57) | 18.7374 |
1990's | 2 (28.57) | 18.2507 |
2000's | 3 (42.86) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 2 (28.57%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (71.43%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |